An evidence map of actigraphy studies exploring longitudinal associations between rest-activity rhythms and course and outcome of bipolar disorders by Scott, Jan et al.
Scott et al. Int J Bipolar Disord            (2020) 8:37  
https://doi.org/10.1186/s40345-020-00200-6
REVIEW
An evidence map of actigraphy studies 
exploring longitudinal associations 
between rest-activity rhythms and course 
and outcome of bipolar disorders
Jan Scott1,2,3, Francesc Colom4,5, Allan Young2,8, Frank Bellivier3,6,7 and Bruno Etain3,6,7* 
Abstract 
Background: Evidence mapping is a structured approach used to synthesize the state-of-the-art in an emerging 
field of research when systematic reviews or meta-analyses are deemed inappropriate. We employed this strategy to 
summarise knowledge regarding longitudinal ecological monitoring of rest-activity rhythms (RAR) and disease modi-
fiers, course of illness, treatment response or outcome in bipolar disorders (BD).
Structure: We had two key aims: (1) to determine the number and type of actigraphy studies of in BD that explored 
data regarding: outcome over time (e.g. relapse/recurrence according to polarity, or recovery/remission), treatment 
response or illness trajectories and (2) to examine the range of actigraphy metrics that can be used to estimate dis-
ruptions of RAR and describe which individual circadian rhythm or sleep–wake cycle parameters are most consistently 
associated with outcome over time in BD. The mapping process incorporated four steps: clarifying the project focus, 
describing boundaries and ‘coordinates’ for mapping, searching the literature and producing a brief synopsis with 
summary charts of the key outputs. Twenty-seven independent studies (reported in 29 publications) were eligible for 
inclusion in the map. Most were small-scale, with the median sample size being 15 per study and median duration of 
actigraphy being about 7 days (range 1–210). Interestingly, 17 studies comprised wholly or partly of inpatients (63%). 
The available evidence indicated that a discrete number of RAR metrics are more consistently associated with transi-
tion between different phases of BD and/or may be predictive of longitudinal course of illness or treatment response. 
The metrics that show the most frequent associations represent markers of the amount, timing, or variability of RAR 
rather than the sleep quality metrics that are frequently targeted in contemporary studies of BD.
Conclusions: Despite 50 years of research, use of actigraphy to assess RAR in longitudinal studies and examination 
of these metrics and treatment response, course and outcome of BD is under-investigated. This is in marked contrast 
to the extensive literature on case–control or cross-sectional studies of actigraphy, especially typical sleep analysis 
metrics in BD. However, given the encouraging findings on putative RAR markers, we recommend increased study of 
putative circadian phenotypes of BD.
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Introduction
In the 2017 update on the global burden of disease dem-
onstrates that, the four most burdensome non-communi-
cable conditions (in terms of DALYs: disability adjusted 
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life years) are: cardiovascular disease (CVD), cancers, 
musculoskeletal conditions, and mental disorders (GBD 
2017; Whiteford et al. 2013). In individuals aged 15–49, 
mental disorders in general, and mood disorders specifi-
cally, are regarded as the most burdensome conditions 
worldwide. In the last 3 to 4 decades, considerable pro-
gress has been made in the management of CVD and 
cancer through precision medicine. The application of 
precision medicine is in its infancy in psychiatry, but 
funding initiatives (such as the European H2020 plat-
form) are supporting studies of personalized diagnostics 
and therapeutics across a range of mental conditions 
including bipolar disorders (BD) (Schumann et al. 2014). 
Like precision approaches to other chronic disorders, 
these studies have largely focused on more quantifi-
able metrics (such as ‘omics’ and brain scanning) as an 
attempt to increase the biological validity of observed 
symptoms (Frey et  al. 2013; Hellwig and Domschke 
2019; MacDonald et al. 2019). This strategy also reflects 
the proposals described in the RDOC (research domain 
criteria) paradigm that identifies key domains and ana-
lytic units for translational research (Cuthbert and Insel 
2013; Insel 2014). Although personalized diagnostics for 
BD are likely to remain a long-term aspiration, there is 
emerging evidence that multi-platform, integrated sci-
ence approaches could offer a pathway for stratifying 
individuals with BD to improve outcome prediction, 
namely treatment response, relapse and recurrence, and 
individual illness trajectories (Scott et  al. 2018). How-
ever, as these efforts progress, there is a need to extent 
the search for phenotypes beyond laboratory settings and 
to test potential biomarkers in real-world settings, such 
as field and cohort studies, comparative effectiveness 
research, and large-scale pragmatic trials (Brietzke et al. 
2019; Scott et al. 2019).
One of the domains identified by RDOC is the arousal 
and regulatory system, and RDOC suggests that sleep–
wake cycle and circadian rhythms (which we will refer to 
as rest-activity rhythms or RAR) represent a core con-
struct for investigation (Insel 2014; Smagula 2016). This 
is of relevance to BD, as converging evidence indicates 
that RAR disruptions can differentiate BD cases from 
healthy controls (HC) and/or other comparator groups 
(Ritter et al. 2011; Geoffroy et al. 2015; Ng et al. 2015; De 
Crescenzo et al. 2017; Scott et al. 2017). Further, real-time 
monitoring of most of these phenomena may be possible 
with wrist-worn devices. Of course, there has been an 
exponential increase in the development and use of con-
sumer grade wearables (and smart phone apps) in clinical 
populations (Faurolt-Jepson et  al. 2012; Krane-Gartiser 
et  al. 2019). However, many demonstrate low inter-
device reliability, none of the apps or programmes are 
currently validated against ‘gold standard’ measures and 
few can accurately estimate key markers of circadian tim-
ing (Zee et al. 2014; FDA 2019; Depner et al. 2020). The 
lack of regulatory approval and absence of basic research 
on or rigour of testing their performance quality means 
consumer devices are not currently recommended for 
use in this research field (Baron 2018; FDA 2019; Moar 
2018). Currently, RDOC indicates that actigraphy could 
be applied as an ‘analytic unit’ for longitudinal studies 
of circadian rhythms and sleep–wake cycles (Cuthbert 
2014). Such studies are now underway, but there is no 
consensus regarding the most useful actigraphy-derived 
RAR parameters to estimate and/or report (Scott et  al. 
2019; Smagula 2016. Also, a preliminary scoping exercise 
of this topic suggested that relatively few actigraphy stud-
ies have employed a longitudinal or prospective design in 
BD. Therefore, we decided to collate any existing publica-
tions on these issues and synthesise the current state of 
knowledge.
This paper has three aims:
(a) To determine the number and type of actigraphy 
studies of samples comprised wholly or partly of 
individuals with BD that explore data regarding: 
outcome over time (e.g. relapse/recurrence accord-
ing to polarity, or recovery/remission), treatment 
response or illness trajectories.
(b) To examine the range of actigraphy metrics that 
can be used to estimate disruptions of RAR and 
describe which individual circadian rhythm or 
sleep–wake cycle parameters are most consistently 
associated with outcome over time in BD.
(c) To demonstrate the use of evidence mapping as a 
process for synthesising the state-of-the-art in the 
field of ecological monitoring of RAR and disease 
modifiers, course of illness, treatment response or 
outcome in BD.
Methods
As the use of evidence-mapping dictates the structure of 
the paper, we provide a brief overview of this approach in 
Table 1. Below, we outline the application to the project 
described in this article.
Rationale for use of mapping
As noted in the introduction, the goal of this evidence 
map is to present an overview of the extent, range, nature, 
and findings of clinical research on RAR metrics meas-
ured by actigraphy and a range of potential outcomes of 
BD. Like many evidence maps, the rationale for using this 
process was determined by prior knowledge of the field. 
Many research groups, including our own, have synthe-
sized research findings or undertaken meta-analyses of 
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pooled data regarding BD cases compared with HC or 
other (comparator) groups (Ritter et  al. 2011; Geoffroy 
et al. 2015). Some of those projects identified small-scale 
studies that used real-time monitoring of BD cases and/
or that examined associations between baseline actigra-
phy recordings and longitudinal course and outcome of 
BD (Scott et  al. 2017). Nearly all of those projects were 
undertaken several decades ago and differences in sam-
pling, diagnosis or research methods meant the publi-
cations failed to meet eligibility criteria for systematic 
reviews focused on a specific research question (De Cres-
cenzo et  al. 2017). Further, it was known that most of 
the reported data were insufficient (in terms of amount 
or quality) to merit inclusion in meta-analyses (Ng et al. 
2015). As such, an evidence map offered a realistic option 
to gain an understanding of existing research in this area, 
especially capturing insights from multiple small-scale 
studies and mapping provides a means of summarizing 
the range of publications and findings in a transparent 
way (Vallarino et al. 2015). The potential advantage over a 
basic narrative or selective review is that the search pro-
cess is reproducible, and the map specifically addresses 
gaps in the knowledgebase (Hetrick et al. 2010). However, 
findings are described in brief, so a map does not aim to 
offer the detailed lists of citations and extensive tables 
included in systematic reviews or meta-analyses.
Mapping process
The process usually incorporates four steps (clarifying 
focus; describing boundaries and ‘coordinates’ for map-
ping; literature search; charting the output maps). After 
consultation among the co-authors, the questions and 
scope of the mapping project were defined as follows-
Step 1: Clarification of the focus of the map.
It was agreed that the focus would be:
(a) What evidence exists on this topic and based on a 
review of study characteristics and methodologies: 
what conclusions can be drawn about the quality of 
evidence?
(b) What areas are, or are not, well-researched?
(c) Based on the available evidence, what advice can be 
offered to clinicians and investigators in the field?
Step 2: Description of the eligibility criteria (boundaries 
for inclusion and exclusion), specification of co‑ordinates 
to be mapped (study characteristics associated 
with outcome/response, etc.) and definition of key variables 
(RAR metrics):
(a) Studies were eligible if:
Inclusion criteria-
i) The sample or cohort was wholly or partly comprised 
of BD cases that met clinical or research diagnostic 
criteria
ii) It reported associations between any RAR actigraphy 
metric recorded at baseline and a clinical or research-
defined outcome assessed at follow-up in BD cases 
(or vice versa). Note: For the purposes of the map, 
the focus was on BD cases, so we extracted informa-
Table 1 Brief overview of evidence mapping
Evidence Mapping
Evidence mapping is defined as-
“a form of knowledge synthesis that addresses an exploratory research question aimed at mapping key concepts, types of evidence, and gaps in research 
related to a defined area or field by systematically searching, selecting, and synthesizing existing understanding”
The gold standard methods used in evidence-based research are systematic review and meta-analysis. These classic approaches are both rigor-
ous and provide readers with detailed information about narrow questions (e.g. the efficacy of drug X for disorder Y). However, developments 
from this archetypal model are now being developed to meet more diverse needs regarding evidence synthesis (Arksey 2003; Miake-Lye et al. 
2016). The obvious example is the use of rapid reviews (which address urgent topics and do not always fully adhere to systematic methodolo-
gies) or scoping reviews (that identify extensive bodies of literature but do not usually provide detailed synthesis) (Colquhoun et al. 2014). In 
this context, evidence mapping has emerged as another process that allows researchers and their audience to develop an understanding of 
the extent and distribution of evidence in on a broad topic, highlighting what is known and also where gaps exist (Katz et al. 2003; Hetrick 
et al. 2010). Although it applies systematic and replicable methodology, the process is iterative, as expert consensus and preliminary literature 
searches inform the next steps in the review, so the final product is broader and less detailed than the traditional approaches (Vallarino et al. 
2015). Furthermore, the goal is not to provide detailed statistical comparisons, but rather to offer an essential snapshot of what is or is not 
known at this moment in time. It is presumed that an evidence map for any given field will be followed up in the future when research devel-
ops to a point where it becomes justifiable to apply more formal reviews and pooled analyses
The depth of evidence synthesized will differ depending on its purpose of an evidence map e.g. an overview of the extent, range and nature of 
research activity might entirely exclude any details of study findings (Miake-Lye et al. 2016). However, if the latter are considered, they can be 
represented by graphs and figures, instead of or as well as a detailed table such as the summary tables provided in systematic reviews (Hetrick 
et al. 2010)
Given the proposed scope of this map, we determined that a simple written summary with basic tables and figures would be offered in the results section 
of the paper. A detailed Table summarizing sample characteristics and research findings (in an Appendix) and citations in the reference list only would 
ensure readers focused on key findings we summarize. Individual readers could then choose to examine supporting evidence and relevant references for 
themes that they wished to investigate further
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tion on inter-individual or intra-individual changes in 
actigraphy or outcomes in the clinical cases (i.e. we 
aimed to avoid focusing on findings of case–control 
studies or cross-sectional comparisons of RAR met-
rics between BD and HC, which have been reviewed 
many times before).
iii) The publication reported any association between 
RAR metrics recorded by actigraphy and the out-
come or response of BD in the short or long term 
(this could include e.g. naturalistic observational 
studies of treatment interventions and/or rand-
omized controlled trials).
iv) Presence of comorbidities was not an exclusion crite-
rion, but details were noted.
v) Findings from self-report questionnaires, consumer 
grade wearables or smartphone apps were eligible if 
the study also reported data for actigraphy record-
ings and/or the RAR findings extracted from ques-
tionnaires or wearables were reported alongside the 
equivalent metric derived from actigraphy.
Exclusion criteria-
The map aimed to capture the extent of the existing 
literature, so there were minimal exclusion criteria. The 
most significant criterion was that studies that failed to 
report any measures (quantity and/or or timing) of day-
time activity were ineligible. Also excluded were single 
case reports or studies where the recruitment of par-
ticipants was not based on a current diagnosis of BD or 
depression (UP and BD) e.g. studies of individuals at risk 
of BD or of individuals attending medical clinics (actigra-
phy has been used to assess treatment outcome in CVD 
and cancer).
(b) Study Coordinates.
It was agreed that the following would be mapped: 
year and geographic location of study (we also noted if 
the study specified seasonality, etc.); sample characteris-
tics (demographics; diagnoses e.g. BD subtypes, inclusion 
of UP and BD; phase of illness at recruitment); commu-
nity or clinical setting (e.g. in- or outpatient); duration of 
study; duration of actigraphy recording; and outcomes 
reported. The latter could include: outcome prediction; 
response to introduction of treatment or treatment with-
drawal; acute or long-term treatment effects; longitudi-
nal course of BD (continuous or repeated cross-sectional 
assessment) in terms of illness progression (naturalist 
follow-up or associated with treatment introduction or 
withdrawal), symptom exacerbation, relapse/recurrence/
recovery/remission and/or putative disease course modi-
fiers (as defined in a study). Also eligible were: naturalistic 
observational studies in clinician settings (unspecified/
uncontrolled treatment), naturalistic monitoring of ill-
ness with unspecified/uncontrolled treatment and/or 
randomized controlled trials that incorporated actigra-
phy (if not identified via previous criteria).
(c) Definitions of Rest-Activity Rhythms.
It is clear from actigraphy studies in BD that the met-
rics reported have differed by location (i.e. geography) 
and decade of study. However, researchers have repeat-
edly acknowledged the close connection between sleep 
and circadian structure and that actigraphy data can be 
used for ‘rhythmometric analysis’ of RAR (Calogiuri et al. 
2013; Smagula, 2016; Wirz-Justice, 2007). As such, all the 
metrics listed in Table 2 are considered as potentially rel-
evant RAR markers in this project.
Table 2 gives an overview of the key RAR metrics that 
have been derived from actigraphy recordings in psy-
chiatry (definitions and descriptions of each metric are 
provided in Table 3 in Appendix) (Calogiuri et al. 2013; 
Ancoli-Israel et  al. 2003). As shown, investigators have 
focused on different rhythmometric procedures, which 
need to be considered when interpreting the map. For 
instance, early studies were likely to report parametric 
statistics (especially in the USA) (Nelson et  al. 1979). 
Three variables (mesor, acrophase and amplitude) were 
estimated using cosinor methods (with the p value 
Table 2 Potential measures of rest-activity rhythms (further details are given in Appendix)
Parametric (Cosinor) Model Non-parametric
Model
Sleep Quantity Analysis Model
(Mean or Variability)
Sleep Analysis- Circadian 
Phase Model
Midline estimating statistic of 
rhythm (MESOR)
Inter-daily Stability (IS) Mean Activity (MA) Sleep Onset
Amplitude Intra-daily Variability (IV) Time in Bed (TIB) (± Lights Off ) Sleep Offset
Acrophase Least active period: L5/ L5 Onset Total Sleep Time (TST) Sleep Midpoint
Most active period:M10/M10 Onset Sleep Onset Latency (SOL) Sleep Regularity Index (SRI)
Amplitude Sleep Efficiency (SE %)
Relative Amplitude Fragmentation Index (FI %)
Wake after sleep onset (WASO) (± N 
awakenings > 5 min)
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signifying the probability that the data really show circa-
dian periodicity), whilst more recently these metrics have 
been derived using regression techniques (which report 
similar variables but assume more complex patterns and 
rhythms and are more robust for larger study popula-
tions) (Fernandez and Hermida 1998). Non-parametric 
methods report a wider range of variables to describe the 
quantity and timing of activity and rest, and especially 
provide insights into variability/stability of rhythms and 
any RAR disruptions (Calogiuri et al. 2013; Natale et al. 
2009). They are often preferred to parametric models and 
it is argued that non-parametric models better represent 
the complexity of RAR than cosinor models (van Some-
ren et al. 1997). Variables derived from basic sleep analy-
sis (such as total sleep time: TST) are probably the most 
widely reported measures in research in BD. One reason 
for this is that these sleep quantity are much easier to 
estimate from raw data (and do not rely on more com-
plex algorithms). Sleep variables are useful for estimating 
duration and fragmentation of sleep patterns but are less 
reflective of circadian rhythmicity. Estimation of variabil-
ity in values for each sleep parameter is encouraged in 
contemporary literature on RAR and greater reporting of 
sleep onset/offset/midpoint or sleep regularity index has 
been employed to give a greater insight into rhythmo-
metrics (Bei et al. 2016).
Step 3: Literature Search
The search approach was the same as utilized in sys-
tematic reviews. Search terms were applied to PubMed, 
MEDLINE, PsycINFO, EMBASE, CINAHL and Web of 
Science databases No limits were set for language, type 
of study or date of publication (the original telemetric 
motion sensors and actometers were used in BD in the 
early 1970s). The search terms included the full range 
of RAR metrics and potential outcomes listed in Step 2, 
supplemented by searches using names of medications 
(e.g. lithium, carbamazepine) or for research groups 
known to have contributed publications when this topic 
initially emerged in the literature. This approach was 
used to ensure the broadest possible range of publica-
tions were identified. Furthermore, hand-searches were 
undertaken of all reference lists of studies noted in nar-
rative reviews, systematic reviews, and meta- analyses on 
this or similar topics. The final list of eligible studies was 
generated based on broad relevance to the scope of this 
map. Key drivers of selection of publications were that:
a) The study reported the use of an actigraphy device to 
undertake daytime or 24-h monitoring of RAR in BD
b) The study endpoint was described in terms of a rec-
ognizable clinical outcome or measure of response or 
change in RAR (if combined with baseline or follow-
up clinical measures).
Step 4. Charting: screening and positioning the relevant 
evidence within the map
Based on the specified aims of the study, we agreed three 
core outputs:
a) Nature & quality of research: a Table of study coor-
dinates was planned. Co-authors would review the 
Table independently and produce a brief written 
synopsis of the key characteristics of the available 
research. This information was used to formulate a 
consensus on the nature and quality of the extant lit-
erature.
b) Extent of research: two maps would be generated. 
The first would describe year and country of study to 
provide a snapshot of research in this field by geog-
raphy and over time. The second map would give 
an overview of the most common methodologies 
and research themes. These would be identified by 
extracting information regarding study coordinates 
and coding each of these separately, e.g. setting (e.g. 
inpatient); type (e.g. naturalistic observational; treat-
ment outcome; response criteria; etc.); reported 
interventions (e.g. proportion of individuals taking 
lithium; numbers allocated to psychological inter-
vention); whether interventions were compared (e.g. 
lithium versus quetiapine). These data could be com-
bined to show the overall pattern of research.
c) A map would be generated to identify the range of 
RAR parameters reported across all studies and 
which individual metrics appeared to be consistently 
found to be associated with course and outcome of 
BD. Such a map can offer a heuristic framework and 
be the starting point for a systematic review or meta-
analysis at a future date.
Results
Twenty-seven independent studies (reported in 29 pub-
lications) were included in the map. Table 4 in Appendix 
gives an overview of the studies and the core character-
istics. To maintain the simplicity expounded in evidence 
mapping we have not included all the citations after every 
statement (the citations are in the reference list and the 
key studies can be easily identified from Table 3).
In the studies in the evidence map, the median age of 
all participants was 45  years and 60% were female. The 
median sample size was 15 per study (range: 2–75); 484 
individuals with BD (out of a total of 560) participated 
in actigraphy and the median duration of recordings was 
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7  days (range 1–210). Studies before 1990 tended to be 
smaller, but sample size did not appear to be determined 
by decade of publication, with several small-scale pro-
jects or BD subsamples (included in larger samples or 
cohorts) being followed-up longitudinally in recent stud-
ies. Overall, 17 studies comprised wholly or partly of 
inpatients (63%). Two studies reported daytime activity 
monitoring only, one study used actigraphy primarily to 
confirm reported patterns of hypersomnia whilst a RCT 
examined changes in objective levels of morning activity 
following a psychological intervention targeted at sleep 
inertia.
There was evidence that statistical analyses of RAR 
have become more sophisticated over time, but earlier 
studies were more likely to address directly the asso-
ciation between RAR and phase of BD (e.g. transitions 
between mania, and depression), and change in RAR fol-
lowing initiation or withdrawal of treatment (especially 
lithium) (e.g. Kripke et  al. 1979; Wolff et  al. 1985). The 
sampling, design, and analytic strategies of most studies 
demonstrate several methodological flaws (e.g. repeated 
testing of small samples with correction, absence of 
reporting of non-significant outcomes). Overall, the con-
sensus judged the quality of the studies to be modest.
Figure  1 shows that > 50% studies (14 of 27) were 
undertaken in the USA and it is only in the last decade 
that the number of studies undertaken across Europe 
has matched the USA. The earliest studies reported the 
seminal work undertaken by Kupfer and associates and 
pursued by researchers at NIMH; more recent studies 
represent projects exploring RAR as disease course mod-
ifiers or examining RAR as potential predictors of treat-
ment response and/or to monitor treatment outcomes. 
Table  3 also demonstrates that there were no studies 
(meeting our eligibility criteria) that reported RAR in BD 
for more than a decade (1994–2006). This is most likely a 
consequence of the fact that psychiatry research shifted 
towards the reporting of metrics favoured by experts in 
sleep/sleep disorders, rather than focusing on metrics 
most relevant to specific psychiatric disorders. Review-
ing publications after 2006 suggests this this trend started 
to reverse when BD researchers increased their focus on 
sleep–wake cycles and also with the rise in interest in 
precision diagnostics and therapeutics.
As shown in Fig. 2, only 22% studies reported follow-up 
assessments at > 6  months (N = 6). Naturalistic observa-
tional studies and treatment outcome studies are equally 
common (N = 10; 37%). In nine studies, > 50% of the sam-
ple were taking lithium or the study specifically explored 
RAR and lithium treatment.
Although our preliminary work for the evidence-map 
identified > 30 possible RAR parameters (parametric 
and non-parametric measures; mean or variable meas-
ures of sleep analysis; putative circadian phase markers 
extracted from sleep quantity analysis), the eligible stud-
ies only consistently reported estimates for seven metrics 
(see Fig. 3). Early studies mainly reported cosinor metrics 
(amplitude, acrophase and mesor), whilst the more recent 
studies increasingly report all raw data (either in the main 
text of the study or Appendices). However, in the middle 
decades, there was a tendency to only report statistically 
significant findings, without any indication as to whether 
other parameters were measured and/or which were 
found to be non-significant. Interestingly, when number 
of studies measuring a parameter is compared with the 
likelihood that a statistically significant association would 
be found, five variables were associated with outcome 
in > 50% of the studies. Namely: Variability/Rigidity of 
RAR (4 out of 4), 24 h rest activity cycle (22 out of 25), 
amplitude (5 out of 6), acrophase/phase advance (5 out of 
7), and sleep efficiency (SE: 5 out of 8). In contrast, most 








=<1980' >1981' >1991' >2001' >2010'
USA EUROPE NEW ZEALAND SOUTH KOREA
Fig. 1 Location of study & decade of publication (Total = 27). (Note: 
if > 1 publication was identified relating to a dataset from a particular 
location, we included the date of the first publication only)
Fig. 2 Key coordinates of actigraphy studies – the graph shows the 
main characteristics or reported purpose of the publications. Note: 
Only descriptors reported in >  = 5 studies are included in the chart. 
However, the Total N reported in the graph exceeds the number 
of citations (n = 28) as most studies are counted in > 1 descriptor 
category
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sleep onset and sleep onset latency (WASO/SOL: 3 out 
of 8) and TST (1 out of 9) being the only metrics showing 
any significant associations.
It was not possible to provide specific evidence of the 
nature of the metrics that were most useful in different 
types of studies, although there was some trend of inter-
est. Using information précised in Table  3, available 
evidence largely supports the view that mania is associ-
ated with circadian phase advance and BD-depression 
with phase delay. The latter was not obvious in studies of 
mixed samples of UP and BD depression. Interestingly, 
treatment may be associated with phase change, and 
treatments may have different effects on phase in BD-II, 
and phase shifts may can be associated with outcome at 
follow-up. The variable 24 h rest-activity cycle represents 
a global estimate of RAR and its primary value to the map 
is that it confirms that RAR can be used to assess a range 
of clinical outcomes in BD. Amplitude appeared to be a 
useful marker of illness course and treatment response 
or outcome. It was noted that variability/rigidity of RAR 
was only estimated in four small samples (Ns = 3, 8, 10, 
12). These studies reported extended continuous dura-
tions of actigraphy and found the metrics to be significant 
markers of longitudinal course (including admissions). 













N Studies Reporng Parameter % Studies Reporng Associaon with Outcome
Key- SE: Sleep efficiency; SOL: Sleep onset latency; TST: Total sleep time; WASO: Wake after sleep onset
Fig. 3 Comparison of number of studies reporting each actigraphy metric & proportion of those studies (%) in which the parameter shows a 
significant association with an outcome of interest
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However, the studies did not report sufficient raw data or 
basic analyses to allow further investigation or interpre-
tation of the findings.
Discussion
This article explores associations between RAR metrics 
measured via actigraphy and course, outcome and/or 
treatment response in BD. The project arose from three 
converging strands of work. First, a background scop-
ing exercise undertaken for the H2020-funded consor-
tium exploring a range of putative markers of lithium 
response phenotypes (including actigraphy) (Scott et  al. 
2019); second, scrutiny of RDOC publications that sug-
gest undertaking longitudinal actigraphy to explore RAR 
phenotypes in BD (Insel 2014); and third, a study of cir-
cadian and sleep–wake cycles in lithium responders and 
non-responders (Scott et  al. 2020). These projects pro-
vided us with sufficient insights into this research field 
and, alongside our prior knowledge, led us to conclude 
that the existing literature on RAR and course/outcome/
response was unlikely to be suitable for systematic review 
or meta-analysis. Furthermore, it appeared it would be 
counter-productive to use these classic evidence-based 
techniques as they would prematurely restrict the focus 
of our investigation to a specific or narrow question of 
what presently seems to be an imprecise research area. 
As such, it was agreed that utilizing evidence mapping 
might enable some synthesis of the diverse range of (pre-
dominantly small-scale) studies currently available.
Regarding our first question (what evidence exists and 
what conclusions can be drawn about the quality of evi-
dence?). We conclude that limited evidence exists, but 
what is available indicates that a discrete number of RAR 
metrics are more consistently associated with transition 
between different phases of BD and/or may be predictive 
of longitudinal course of illness or treatment response. 
The metrics that show the most frequent associations 
represent markers of the amount, timing, or variability 
of RAR rather than the sleep quality metrics that are fre-
quently targeted in contemporary studies of BD. How-
ever, these putative ‘circadian’ signals should be viewed in 
context, as there is evidence of selective reporting of both 
metrics and outcomes, thus increasing the likelihood 
of publication bias. Notably, the statistical associations 
reported derive from multiple small-scale studies that 
together included < 500 individuals with BD. In sum, the 
findings are of interest, encourage pursuit of research in 
this field, but clearly expose that the quality of evidence 
and available published studies is modest.
Next, the second question addressed what areas are, 
or are not, well-researched? Our findings about the 
extent, nature and quality of the research, indicate that 
the available publications demonstrate the diverse ways 
in which RAR can be studied in the context of BD, but 
that no single area has been targeted for a prolonged 
period of research. Notably, the early studies showed a 
keen interest in treatment response (or change in illness 
with treatment withdrawal), but these themes were not 
pursued to a definitive conclusion. However, this theme 
is now drawing interest again and two recent studies 
used actigraphy to explore RAR and acute treatment out-
come, namely ketamine infusions for depression (albeit 
in sample with many more UP than BD cases) and inpa-
tient treatment of mania (such as Blue Blocking Glasses) 
(Duncan et  al. 2017; Henriksen et  al. 2020). The map 
also highlights evidence that clinical depressive symp-
toms are associated with robustness of circadian rhythm 
(e.g. Hwang et  al. 2017), whilst current RAR patterns 
may predict future mental state (Salvatore et  al. 2008). 
Also, in a small inpatient sample, it was shown that RAR 
recorded by actigraphy were associated with clinical pro-
gress, whilst estimates made with a consumer wearable 
were not (Averill et  al. 2019). This is a useful reminder 
that research grade devices are still more accurate than 
consumer grade device and apps (and so actigraphy is 
likely to continue to have a role in the immediate future). 
Importantly, individuals with BD are prepared to wear 
actiwatches and/or consumer devices for extended peri-
ods (> 6  months) and this, allied with new conceptual-
izations of and analytic approaches to of RAR (such as 
fractal activity as an indicator system adaptability and 
lagged data analyses, etc.), may lead to a greater under-
standing of the chronological sequence of change of 
RAR, mood, cognition and other cardinal features of BD 
(Knapen et al. 2020; Walker et al. 2020).
The final question asked, based on the available evi-
dence, what are the potential ways forward for the field? 
We suggest that one important option would be to 
develop a consensus within research consortia or wider 
groups of clinicians and investigators regarding the most 
appropriate RAR metrics to include in future actigra-
phy studies of BD (Scott et  al. 2017). It is particularly 
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important that this dialogue focuses on metrics that offer 
insights into RAR in BD that will have the optimal clini-
cal as well as research utility for this field. This should be 
prioritized over simply generating a list of RAR measures 
recommended for estimation or reporting of sleep or 
sleep–wake research in general (Sack et al. 2007). These 
discussions will necessarily consider any RAR metrics 
that may represent trait or state variables (e.g. there is 
emerging evidence that relative amplitude, amplitude, 
interdaily stability and intradaily variability may be 
markers of disease onset as well as disease progression) 
(Merikangas et al. 2019; Scott et al. 2020). Developing a 
consensus is perhaps the most important recommenda-
tion that arises from this mapping exercise, as without 
such a course of action there is a clear possibility that we 
will continue to lack the means to make detailed cross-
study comparisons of the metrics that would offer most 
promise as diagnostic or response biomarkers.
An obvious gap in the available literature is the lack 
of youth studies of actigraphy that take a longitudinal 
perspective. Given the interest in staging models and 
temperament, research on the transition between sub-
threshold conditions or at-risk mental states and the 
onset of full-threshold illness episodes would be wel-
come. In individuals with established BD, consideration 
should be given to RAR metrics that might be com-
bined in multi-platform research of precision diagnos-
tics and therapeutics (Scott et  al. 2019). For instance, 
precision studies that focus on prediction of response to 
mood stabilizers such as lithium, and the identification 
of biosignatures (rather than single biomarkers) might 
consider giving priority to reporting RAR markers such 
as amplitude and variablility (given our mapping findings 
regarding emerging evidence for their importance). The 
mapping exercise demonstrated that actigraphy stud-
ies are viable in inpatient as well as outpatient settings, 
as such, wider consideration should be given to monitor-
ing inpatient progress using objective measures such as 
actigraphy, with the option of continuation to post-dis-
charge settings. Of course, longitudinal monitoring that 
allows early warning signs of relapse or recurrent is also 
feasible with this ecological measure (Bellivier et al. 2015; 
Ritter et  al. 2011). The above steps would address some 
of the explicit aims outlined by RDOC publications but 
could be valuable for clinicians e.g. they might consider 
using electronic monitoring or including sleep diaries as 
part of the clinical assessment of BD. The latter could be 
scrutinized not only to identify mean sleep duration and 
timing but also variability between weekdays and week-
ends or large differences in duration of sleep onset/offset/
duration over 2–3 weeks.
Whilst consumer grade wearables and smart phone 
apps are attractive to many, it is important to remember 
that they all await regulatory approval for use as clinical 
devices (and commercial developments of longer bat-
tery life to avoid repeated need for charging). However, 
their use alongside actigraphy could be helpful, both to 
validate different measures of RAR that might be derived 
from consumer devices but also to facilitate ecological 
momentary assessment (EMA) research (Merikangas 
et  al. 2019; Depner et  al. 2020). Research in this area is 
ongoing and has the advantage of combining self-report 
ratings of events, cognition, energy, and mood states with 
objective RAR data (de Wild-Hartmann et al. 2013; Meri-
kangas et al. 2019). However, these advances necessarily 
require researchers to work more closely alongside stat-
isticians and computational data scientists as the optimal 
methods for analyzing and understanding links between 
RAR, symptoms and behaviours are more sophisticated 
(including non-linear dynamics, entropy) than the basic 
approaches that are most commonly used and/or the 
algorithms that are currently available. Assuming this 
dialogue can occur, combining these approaches would 
allow to comprehensive exploration of the course of ill-
ness, prediction of treatment response and a range of 
patient reported outcomes (Moskowitz and Young, 2006; 
Marino et  al. 2013). For clinicians, actigraphy offers 
access to objective ecological monitoring that provides a 
far more reliable and valid measure of RAR than can be 
obtained by self-rating scales (Depner et  al. 2020; Mul-
ligan 2016). However, not all clinicians feel confident in 
extracting data and metrics from the devices and this is 
likely to mitigate against wider dissemination beyond 
specialist settings. Another advantage of actigraphy is 
that it is a more feasible option for routine clinical prac-
tice than putative ‘omic’ and brain scanning markers of 
treatment response or illness outcome as these are less 
available, more expensive and often concentrated in 
research settings (Gooley and Chua 2014). Also, if the 
focus is on RAR, then actigraphic monitoring would be 
easier to integrate into a clinical management and moni-
toring package than evaluation of other objective circa-
dian markers e.g. measurement of dim light melatonin 
onset (DLMO) (Depner et al. 2020).
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Conclusions
Despite 50  years of research, and several papers iden-
tified by this evidence map being highly cited, use of 
actigraphy to assess RAR in longitudinal research and 
examination of these metrics and treatment response, 
course and outcome of BD is under-investigated. This is 
in marked contrast to the extensive literature on case–
control or cross-sectional studies of actigraphy, espe-
cially typical sleep analysis metrics in BD, which are 
reported in independent studies, systematic reviews, 
meta-analyses and meta-regressions. The most obvi-
ous reason for this marked disparity in the amount of 
research undertaken using these different methodolo-
gies, is that case–control and cross-sectional studies 
are easier to undertake, usually involve much briefer 
time frames, and have lower resource requirements 
than longitudinal research. Also, it was notable that 
prospective studies identified in this evidence map were 
still predominantly shorter-term projects, often report-
ing outcomes over weeks rather than months.
This evidence map suggests that the existence of sev-
eral often-quoted publications has probably led to an 
overestimation of the extent and robustness of existing 
evidence of longitudinal associations between RAR and 
treatment response, course, and outcome in BD. How-
ever, we are aware of promising emerging findings in 
this area (McCarthy et  al. 2019; Scott et  al. 2020) and 
there is tremendous potential for expanding this field of 
research to inform precision medicine projects in psy-
chiatry. Further, there is a strong argument that, rather 
than actigraphy being replaced by consumer grade 
devices and apps, it may be more fruitful to establish 
frameworks for clinical and research projects that com-
bine these approaches.
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Appendix
See Tables 3 and 4.
Table 3 Parameters reported in studies of Rest–Activity Rhythms: additional details
Cosinor model descriptions from Nelson et al (1979); nonparametric approach descriptions from Van Someren et al (1997). Sleep quantity analysis variables and 
descriptions as from Natale et al (2009), Krane-Gartiser et al. (2019) and Bei et al (2016)
IS quantifies regularity in activity (overall variability in a time-signal after averaging across days) & IV quantifies fragmentation; some argue that SRI best quantifies 
how rapidly sleep patterns change between consecutive days
Cosinor model (parametric)
Midline estimating statistic of rhythm (MESOR) Estimates the arithmetic mean of the values throughout the 24-h period
 Amplitude Distance from the rhythmic mean to the peak or trough of a mathematical model
 Acrophase Time interval during which the highest values are expected
Nonparametric approach
 Interdaily stability Quantifies the degree of resemblance between the activity patterns on individual days; ranges 
from 0 to 1 and may typically be about 0.6 for healthy adults
 Intradaily Variability Quantifies the fragmentation of periods of rest and activity; ranges from 0 to 2 and typically is < 1 
for healthy adults, with higher values indicating a more fragmented rhythm
 L5 Average of the activity values for the 5 least active consecutive hours in the 24-h cycle
 L5 Onset Onset time of the five most restful consecutive hours
 M10 Average of the activity values for the 10 most active consecutive hours in the 24-h cycle
 M10 Onset Onset time of the 10 most active consecutive hours
 Amplitude Difference between M10 and L5
 Relative Amplitude Calculated by dividing AMP by the sum of L5 and M10; ranges from 0 to 1, with higher values 
indicating higher amplitude of the rhythm
Sleep quantity analysis
(reported as Individual Mean values or Intra-Individual Variability e.g. SD, RMSSD)
 Time in bed (TIB)
(Lights Off (LO))
Difference between the get-up time and bedtime
(Lights Off: time bedroom lights are turned off is reported in some therapy studies)
 Total sleep time (TST) Duration of the sleep episode, calculated on the actual time of sleep start and sleep end
 Sleep latency (SOL) Difference between time in bed and the actual time the monitored subject starts sleeping
 Mean activity (MA) Number of movements within specified epoch (usually 1 min)
 Number of awakenings longer than 5 min (NA > 5) Number of awakenings longer than 5 min
 Wake after sleep onset (WASO) Wake time (min) after sleep onset
 Sleep efficiency (SE %) Percentage of effective sleep during time in bed
 Fragmentation Index
(FI %)
% of sleep continuity/discontinuity. It is calculated as the amount of time associated with move-
ment (restlessness) during the sleep period expressed as a percentage
Putative Circadian Phase Measures (derived from Sleep quantity analysis data)
 Sleep Onset Time is the clock time (HH:MM) of the first epoch scored as sleep in each main rest interval
 Sleep Offset Mean sleep offset time is the clock time (HH:MM) of the last epoch scored as sleep in each main 
rest interval
 Sleep midpoint Calculated as the midpoint between sleep onset and sleep offset
 Sleep Regularity Index (SRI) This is defined as the percentage probability of a person being asleep (or awake) at any two time 
points 24 h apart
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